Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between 10 months and 16 years old born with hearing loss caused by gene mutations.

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one-time treatment.

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s treatment, new data show.

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic deafness.

Regeneron (NASDAQ:REGN) reported positive updated results from a Phase 1/2 study of its gene therapy DB-OTO in the treatment of profound genetic hearing loss in children due to certain variants of the OTOF gene.